Targeted Oncology

FDA Orphan Drug Status Granted to Anti-CDH17 ADC in Pancreatic Cancer

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal ...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...
Managed Healthcare Executive

AI platform identifies pancreatic cancer patient subgroup with threefold Increase in survivability | 2026 ASCO Gastrointestinal Cancers Symposium

BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated ...

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in M…

Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first ...
Managed Healthcare Executive

GLP-1s outdo aspirin in colorectal cancer prevention, study finds | ASCO Gastrointestinal Cancers Symposium

GLP-1 drugs are 36% more effective than aspirin in reducing colorectal cancer risk, with fewer side effects like acute kidney ...
Business Wire

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing ...

Global Colon Cancer Association Launches Biomarker Testing Campaign at ASCO GI

New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.